RxDoctor Payments Data

Brian Jones, MD

Interventional Cardiology · Baton Rouge, LANPI 1184828873

Payments from drug & device makers

$665in general payments, 2019–2025

Across 16 payments — averaging $41.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$256
  • Shockwave Medical, Inc$107
  • Cvrx, Inc.$96
  • Novartis$78
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$42
  • Amgen$27
  • plus $59 from 3 others

What the payments were for

  • Food & beverage$665100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$665 in reported general payments places this provider in the 0th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$106,944
Medicare patients
1,035
Services billed
2,031

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban623$506,381
Repatha SureclickEvolocumab384$221,590
EntrestoSacubitril/Valsartan170$142,734
XareltoRivaroxaban149$134,430
JardianceEmpagliflozin57$55,204
BrilintaTicagrelor76$41,535
Praluent PenAlirocumab82$41,255
FarxigaDapagliflozin Propanediol53$32,628
Ranolazine ErRanolazine278$17,105
Metoprolol Succinate847$11,325
Rosuvastatin Calcium488$7,054
Janumet XrSitagliptin Phos/Metformin Hcl12$6,562
Isosorbide Mononitrate ErIsosorbide Mononitrate636$6,491
Atorvastatin Calcium657$6,442
Prasugrel Hcl121$4,114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$78$142,734170 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 0th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →